VRTX news

Vertex Pharmaceuticals reported Q3 revenue of $3.44 billion, up 12%, and raised full-year revenue guidance to $13.15 to $13.25 billion. The company also closed the acquisition of Crinetics Pharmaceuticals and is preparing for approval of povetacicept in renal medicine.

Virtuix appointed M&K CPAS as its new auditor, prompting the firm to confirm financial statements in an SEC 8-K letter.

Vertex Pharmaceuticals agreed to acquire Crinetics for $85 per share. Net product revenue for the quarter was $24.0 million.

AbCellera collaborated with Vertex Pharmaceuticals to develop multispecific T-cell engagers, receiving $28.1 million in upfront payments. The deal strengthens AbCellera's position in the advanced autoimmune and immunology markets.

Vertex Pharmaceuticals announced plans to acquire Crinetics Pharmaceuticals to bolster its pipeline and revenue projections. The deal is fully funded by committed bridge financing and is expected to contribute to significant growth and accretion by 2029.

Virtuix Holdings amended a warrant to lower the exercise price to $3.00 per share during a defined period. This adjustment aims to incentivize investors to exercise their warrants and is effective upon the filing of a registration statement update.

Virtuix Holdings amended its equity financing warrant with Streeterville Capital, reducing the exercise price to $4.00 per share through June 1, 2026, with the company retaining termination rights. The amendment reflects ongoing capital structure adjustments for the VR technology company.